260 related articles for article (PubMed ID: 27864834)
1. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis.
Ohnuma T; Matsuzawa T; Kinoshita M; Sano S; Kawamura T; Shimada S; Inozume T
J Dermatol; 2017 Nov; 44(11):1325-1326. PubMed ID: 27864834
[No Abstract] [Full Text] [Related]
2. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
3. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
4. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
[TBL] [Abstract][Full Text] [Related]
5. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
6. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
7. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
[No Abstract] [Full Text] [Related]
8. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.
Tiu C; Pezaro C; Davis ID; Grossmann M; Parente P
Asia Pac J Clin Oncol; 2015 Jun; 11(2):190-4. PubMed ID: 25855890
[TBL] [Abstract][Full Text] [Related]
9. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
10. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
Namikawa K; Takahashi A; Mori T; Tsutsumida A; Suzuki S; Motoi N; Jinnai S; Kage Y; Mizuta H; Muto Y; Nakano E; Yamazaki N
Melanoma Res; 2020 Feb; 30(1):76-84. PubMed ID: 31095037
[TBL] [Abstract][Full Text] [Related]
12. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.
Schermers B; Franke V; Rozeman EA; van de Wiel BA; Bruining A; Wouters MW; van Houdt WJ; Ten Haken B; Muller SH; Bierman C; Ruers TJM; Blank CU; van Akkooi ACJ
Br J Surg; 2019 Apr; 106(5):519-522. PubMed ID: 30882901
[TBL] [Abstract][Full Text] [Related]
13. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
14. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Ansorge C; Seufert J; Meiss F; von Bubnoff D
J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
[No Abstract] [Full Text] [Related]
15. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
18. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
Yokota K; Uchi H; Uhara H; Yoshikawa S; Takenouchi T; Inozume T; Ozawa K; Ihn H; Fujisawa Y; Qureshi A; de Pril V; Otsuka Y; Weber J; Yamazaki N
J Dermatol; 2019 Dec; 46(12):1197-1201. PubMed ID: 31638282
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
Tacar SY; Selcukbiricik F; Yilmaz M; Erturk K; Murat Sarici A; Gulturk I; Ayhan M; Tural D
Melanoma Res; 2021 Oct; 31(5):449-455. PubMed ID: 34039945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
